Eckert & Ziegler stock holds steady after recent consolidation

Published on 09/11/2026 at 22:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock was last quoted at EUR 12.26 on Xetra as of September 10, 2026, leaving the shares 2.36 percent below their level at the start of the year. Recent half-year figures and guidance remain key for investors watching the medtech supplier.

Photorealistischer Reinraum einer radiopharmazeutischen Produktionsanlage — Eckert & Ziegler DE0005659700 Medizintechnik: Forscher arbeiten in modernem Radiopharmazeutika-Reinraum mit Gloveboxen und Hot-Cells, Illustration mit AI erstellt.

Eckert & Ziegler stock (ISIN DE0005659700) most recently changed hands at EUR 12.26 on Xetra as of September 10, 2026, leaving the shares 2.36 percent below their level at the start of the year and reflecting a consolidation phase after earlier gains.

Share price consolidates below recent highs

According to MarketScreener on September 10, 2026, Eckert & Ziegler stock closed at EUR 12.26 on its German home market, with a five-day performance of minus 1.37 percent and a year-to-date change of minus 2.36 percent.

The current level leaves the shares at a discount to typical medtech peer valuations and signals that the market is waiting for the next operating update before rerating the stock. For medium-term investors, the recent pullback can only be understood in the context of the company’s latest reported figures and guidance.

Ownership structure underpins long-term strategy

MarketScreener’s latest overview also highlights a concentrated ownership structure as of September 10, 2026, with company founder Andreas Eckert holding 31.16 percent of Eckert & Ziegler’s outstanding shares, corresponding to a valuation of about EUR 299 million at the current share price, while the company itself holds 1.494 percent in treasury shares valued at around EUR 14 million.MarketScreener

Institutional investors account for roughly 7 percent of the register, while unidentified shareholders make up about 60.35 percent of the free float, illustrating that the stock remains widely held among smaller investors even as strategic holdings stay high.MarketScreener

Recent fundamentals guide investor expectations

In its most recently reported interim figures for the first half of 2026, Eckert & Ziegler posted revenue and earnings that remain the central reference point for valuing the stock in September 2026, with investors closely tracking margin development and order trends in its radioisotope and radiopharma segments, according to Eckert & Ziegler’s investor information.Eckert & Ziegler

The company’s latest available guidance for fiscal year 2026 provides the benchmark against which the current share price of EUR 12.26 and the year-to-date change of minus 2.36 percent are being assessed, making upcoming quarterly updates and any revisions to revenue or earnings targets a potential catalyst for Eckert & Ziegler stock.Eckert & Ziegler

Stock level and investor perspective

As of September 10, 2026, Eckert & Ziegler stock is quoted at EUR 12.26 on Xetra, representing a five-day performance of minus 1.37 percent and a year-to-date change of minus 2.36 percent, which keeps the shares in a consolidation zone as investors await the next set of operating figures to reassess valuation.